Email Us
Call Us
AUSTIN, Texas – November 9, 2023 – The validation of ten in-house lung cancer xenograft models by Altogen Labs has been carried by pharmaceutical and biopharma trade media internationally, extending awareness of the company’s oncology model portfolio to drug development audiences across North America, Europe, and Asia.
The announcement drew attention because the underlying problem is well understood by anyone running a lung program: only a small fraction of compounds effective in vitro remain effective in vivo. Model selection is not a procurement detail. It is one of the highest-leverage decisions in a preclinical program, and a laboratory that offers only one or two lung models is effectively deciding the outcome in advance.
Altogen Labs validated models include A549, H460, NCI-H226, NCI-H1975, DMS273, Calu-3, Calu-6, H1155, H1703, H1993, HCC827, LL2, and NCI-H526/H522, available alongside patient-derived xenograft options. Together they capture the heterogeneity of lung carcinoma across morphology, driver genetics, and stage-specific phenotype, allowing sponsors to test a compound against the biology it will actually encounter rather than a single convenient proxy.
Each model is available in subcutaneous, orthotopic, and metastatic configurations. Study packages include tumor growth delay analysis, hematology, histopathology, biomarker screening, pharmacokinetic analysis, biodistribution, and imaging, delivered with complete raw data and statistical treatment.
Altogen Labs has performed preclinical oncology research since 2009 from its GLP-compliant, IACUC-regulated facility in Austin, Texas, and supports clients from study design through patent filing and regulatory submission.
About Altogen Labs Altogen Labs is a professional, experienced, and highly reputable GLP-compliant contract research organization providing preclinical research and biology CRO services worldwide, offering a large collection of in-house validated xenograft models (CDX, PDX, syngeneic, organoids, NAMs) and extensive experience in efficacy xenograft studies and safety toxicology studies.
Contact Information: Altogen Labs | 11200 Menchaca Rd, Bldg 2, Suite 203 | Austin, TX 78748 USA Tel: 512-433-6177 | Email: info@altogenlabs.com | Web: altogenlabs.com
Sources: Pharmaceutical-Tech, BioPharma Boardroom, StreetInsider, other.